Cat. No.: HY-112579

Ceftobiprole

(Synonyms: Ro 63-9141; BAL 9141)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC₉₀ value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens. Ceftobiprole can be used for the study of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia.

For research use only. We do not sell to patients.

Purity: 97.22%
CAS No.: 209467-52-7
Formula: C₂₀H₂₂N₈O₆S₂
Molecular Weight:534.57

Storage:

Powder -20°C, 3 years , 4°C, 2 years

* The compound is unstable in solutions, freshly prepared is recommended.

Ceftobiprole Chemical Structure

CAS No.: 209467-52-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

β-lactam

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
THP-1	EC₅₀	0.07 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.07 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.08 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.19 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.2 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.2 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.2 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.205 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.23 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.25 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.26 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.41 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.41 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.41 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.7 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.73 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.82 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.88 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.94 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	1.23 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]

In Vitro

Ceftobiprole (Ro 63-9141) has demonstrates activity against important gram-positive bacteria, including S. pneumonia (PRSP), Methicillin-resistant S. aureus (MRSA), and E. faecalis with MIC₉₀ values of 0.25, 2, and 2 mcg/mL, respectively. Ceftobiprole has also demonstrated potent in vitro activity against several clinical isolates of community-associated Methicillin-resistant S. aureus (CA-MRSA), S. aureus (VISA), and S. aureus (VRSA), with a minimum inhibitory concentration (MIC) of 2 mcg/mL^[1].
Ceftobiprole is highly active against S. aureus, withMICs ranging from 0.12 to 4 mg/L (only one resistant strain,MIC of 4 mg/L). Furthermore, Ceftobiprole is twice more active on Methicillin-susceptible S. aureus (MSSA) strains with MIC₅₀ and MIC₉₀ of 0.5 mg/L than on MRSA strains with MIC₅₀ and MIC₉₀ of 1 mg/L. Moreover, Panton-Valentine leukocidin (PVL)+MRSA are slightly more susceptible to Ceftobiprole (MIC₅₀ of 0.5 mg/L and MIC₉₀ of 1 mg/L) than PVL-MRSA (MIC₅₀ and MIC₉₀ of 1 mg/L)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 209467-52-7
Appearance Solid
Molecular Weight 534.57
Formula C₂₀H₂₂N₈O₆S₂
Color Light yellow to yellow
SMILES

O=C(C(N12)=C(/C=C3C(N([C@H]4CNCC4)CC/3)=O)CS[C@]2([H])[C@H](NC(/C(C5=NSC(N)=N5)=N\O)=O)C1=O)O
Synonyms

Ro 63-9141; BAL 9141
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (3)

All

Sort by:

Journal Impact Factor

Nat Microbiol

Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]

2023 Mar;8(3):410-423. PMID: 36759752
Antibiotics (Basel)

Identification of Staphylococcus aureus Penicillin Binding Protein 4 (PBP4) Inhibitors. [Abstract]

2022 Oct 4;11(10):1351. PMID: 36290009
Pathology

In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates. [Abstract]

2026 Feb 6:S0031-3025(26)00393-4. PMID: 41760492

Solvent & Solubility

In Vitro:

DMSO : 4.95 mg/mL (9.26 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8707 mL

9.3533 mL

18.7066 mL

5 mM

0.3741 mL

1.8707 mL

3.7413 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.5 mg/mL (0.94 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.5 mg/mL (0.94 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.5 mg/mL (0.94 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kisgen J, et al. Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). P T. 2008 Nov;33(11):631-41. [Content Brief]

[2]. Hodille E, et al. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Med Mal Infect. 2017 Mar;47(2):152-157. [Content Brief]

[3]. E Azoulay-Dupuis, et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother. 2004 Apr;48(4):1105-11. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8707 mL	9.3533 mL	18.7066 mL	46.7666 mL
DMSO	5 mM	0.3741 mL	1.8707 mL	3.7413 mL	9.3533 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ceftobiprole

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Ceftobiprole

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ceftobiprole

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Ceftobiprole

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ceftobiprole Related Classifications

Cat. No.: HY-112579